Navigation Links
Moderna Therapeutics Named a "Fierce 15" Biotech Company for 2013
Date:9/24/2013

CAMBRIDGE, Mass., Sept. 24, 2013 /PRNewswire/ -- Moderna Therapeutics, the pioneering company developing messenger RNA therapeutics™, a revolutionary new treatment modality to enable the in vivo production of therapeutic proteins, announced today that FierceBiotech has named Moderna as one of 2013's Fierce 15.

The award designates Moderna as one of the most promising private companies in the biotech industry. Companies from around the world are selected based on strength of technology, venture funding, and their potential to positively impact the treatment of human diseases.

"With its messenger RNA therapies, Moderna has the potential to reinvent the way protein therapies are developed and created," says Executive Editor Ryan McBride. "AstraZeneca validated this potential in a landmark deal that gives Moderna the cash and resources to become a major player in oncology and rare diseases, making this company one to watch closely."

"We are honored to be selected as a Fierce 15 company and recognized for our vision in the field of messenger RNA therapeutics™," said Stephane Bancel, president and founding CEO of Moderna. "This award comes at an exciting time for us, as we recently published our first proof of concept study in Nature Biotechnology, providing important validation of our platform's potential to treat many diseases that cannot be addressed today. We are thrilled to be moving forward quickly and safely to translate our technology into treatment for patients in need."

About Moderna Therapeutics

Moderna is pioneering messenger RNA therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn active intracellularly or secreted. This breakthrough platform addresses currently undruggable targets and offers a superior alternative to existing drug modalities for a wide range of disease conditions. Moderna has developed a broad intellectual property estate, including 144 patent applications with 6,910 claims ranging from novel nucleotide chemistries to specific drug compositions. The company plans to develop and commercialize its innovative messenger RNA drugs—initially for rare diseases and oncology—while partnering drug candidates in other therapeutic areas in order to rapidly deliver this innovation to patients. Moderna is a privately held company based in Cambridge, Mass. Visit www.modernatx.com to learn more.

About FierceBiotech

FierceBiotech is the biotech industry's daily monitor – a free email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval and regulation, biotech company deals and more. More than 90,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day's top stories. Sign up is free at www.fiercebiotech.com.

For information contact:
Dan Quinn
617-761-6732
Dan.Quinn@fkhealth.com


'/>"/>
SOURCE Moderna Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Henri A. Termeer Joins Moderna Therapeutics Board Of Directors
2. Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer
3. Biotech Industry Veteran Joseph Bolen Joins Moderna Therapeutics to be President of Research and Development
4. Study Published in Nature Biotechnology Demonstrates Ability of Modernas Novel Therapeutic Paradigm to Repair and Regenerate Damaged Heart Tissue
5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
7. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
8. Fate Therapeutics Strengthens Its iPSC Platform
9. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
10. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
11. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... CA (PRWEB) , ... November 30, 2016 , ... ... a new moving magnet Voice Coil Actuator with a flexure design that ensures ... long life with cost-effective pricing and is ideally suited where extreme precision is ...
(Date:11/30/2016)... 2016  The Allen Institute for Cell Science ... publicly available collection of gene edited, fluorescently tagged ... cellular structures with unprecedented clarity. Distributed through the ... are a crucial first step toward visualizing the ... makes human cells healthy and what goes wrong ...
(Date:11/30/2016)... 2016 Part of 5m$ Investment in ... ... Aptuit, LLC today announced that it had successfully completed the ... compounds have increased the Screening Collection to over 400,000. The ... capabilities of the company. This expansion, complemented by new robotics ...
(Date:11/30/2016)... ... November 30, 2016 , ... On 28 November 2016, the International Union of ... nihonium (Nh), moscovium (Mc), tennessine (Ts), and oganesson (Og), respectively for element 113, 115, ... proposed by the discoverers have been approved by the IUPAC Bureau. The IUPAC Council ...
Breaking Biology Technology:
(Date:11/15/2016)... 15, 2016 Research and Markets has announced ... 2021" report to their offering. ... ... by 2021 from USD 6.21 Billion in 2016, growing at a ... of the bioinformatics market is driven by the growing demand for ...
(Date:6/27/2016)... 2016 Research and Markets has announced the ... report to their offering. The ... to grow at a CAGR of 12.28% during the period ... an in-depth market analysis with inputs from industry experts. The report ... years. The report also includes a discussion of the key vendors ...
(Date:6/22/2016)... , June 22, 2016 On Monday, the ... to industry to share solutions for the Biometric Exit ... Customs and Border Protection (CBP), explains that CBP intends ... departing the United States , in ... to defeat imposters. Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
Breaking Biology News(10 mins):